591 results about "Tumor target" patented technology

The invention discloses a bovine serum albumin combined nano antibody and a preparation method and application thereof, the amino acid sequence of the bovine serum albumin combined nano antibody Nb1 is shown as SEQ.ID No.1, the nano antibody Nb not only has high affinity to bovine serum albumin, but also has good binding activity to both human serum albumin and mouse serum albumin, and the nano antibody Nb has high affinity to human serum albumin and mouse serum albumin. And the antibody has a relatively good broad-spectrum application range, and can be widely applied to the aspects of drug half-life period enhancement, tumor targeted therapy and imaging, immunodetection or diagnosis, recombinant albumin purification or enrichment and the like.

The invention relates to the technical field of tumor treatment, in particular to an intelligent decision-making system for tumor precise targeted medication based on individual mutation information, which comprises a data processing layer, a variation annotation and function prediction layer, a knowledge base integration layer and a scheme decision-making engine and report visualization module. According to the intelligent decision-making system for tumor precise targeted medication based on individual mutation information, a rule engine and a prediction model are combined, dynamic priority ranking is output, multi-model fusion decision making is achieved, and clinical scene deep adaptation is achieved by predicting primary and secondary drug resistance, calculating liver and kidney function adjusting dosage and generating a combined medication time sequence scheme; through an individualized drug delivery scheme, combination drug use optimization is achieved, a visual clinical report is generated, clinical executable operation is further strengthened, and through algorithm quantification, a dynamic knowledge graph, AI auxiliary decision making and a clinical operation closed loop, the next-generation technical research direction of a tumor precise drug use system can be represented.

The invention discloses a multi-angle particle therapy system without a rotating rack and a using method thereof, and relates to the technical field of particle therapy equipment, and the treatment system comprises an accelerator, an irradiation system, a control system, a patient supporting system and an imaging system. The patient supporting system comprises a containing and fixing device, a two-dimensional translation system, a rotating system and a multi-degree-of-freedom mechanical positioning system, the containing and fixing device is connected with the two-dimensional translation system, the two-dimensional translation system is connected with the rotating system, and the two-dimensional translation system controls the relative position of a patient and a rotating center; the rotating system rotates a patient to an appointed angle of a treatment plan or cooperates with the imaging system to obtain a three-dimensional image of the patient, and the irradiation system irradiates a tumor target area; the use method comprises the following steps: generating a treatment plan by reconstructing a three-dimensional CT image, and completing irradiation at different angles according to the treatment plan. According to the treatment system, multi-angle irradiation on a patient can be realized under the condition that a rotating rack is not used, and the manufacturing period and cost of the particle treatment system can be reduced.

The invention discloses a tumor radiotherapy dose calibration method, and relates to the technical field of tumor radiotherapy, and the method comprises the steps: collecting multi-modal data in real time through 4D-CT, MRI and the like, extracting dynamic features through space-time registration, calculating a risk organ dose ratio and a tumor target dose deviation rate, and constructing a comprehensive evaluation function. The method has the advantages that the multi-modal dynamic data of the tumor target area are synchronously collected in real time, the space-time joint registration algorithm and the time sequence weight factor are combined, the limitation that existing static calibration depends on fixed parameters is broken through, and the method is suitable for the multi-modal dynamic data of the tumor target area. According to the method, 95% dose coverage of a tumor target region is guaranteed, and meanwhile, organ-endangering peak value receiving amount is controlled within a certain range of a clinical tolerance threshold value, so that the risk of excessive irradiation of normal tissues is reduced, and the radiotherapy dose calibration precision is prompted based on the deviation rate of a traditional method.

The invention discloses an AIE type fluorescent probe with tumor targeting as well as preparation and application thereof, and belongs to the technical field of medicines, the probe can accurately target HDAC6 high-expression tumor cells, the specific binding capacity of the probe reduces interference to normal cells, and the detection accuracy is improved. The probe is fused with AIE performance dye molecules and emits strong fluorescence during aggregation, so that the imaging sensitivity and definition are remarkably enhanced. By optimizing the structure and synthesis conditions, the fluorescence intensity and stability of the probe are improved, the sensitivity of early tumor detection is ensured, and the survival rate and life quality of patients are improved. The preparation method is simple, convenient, feasible, low in cost and beneficial to practical application. The probe can be used for preparing tumor detection products, assisting in tumor diagnosis and classification, monitoring treatment changes and evaluating the curative effect. High-precision imaging can be realized in the aspect of tumor imaging, the method can be used for evaluating curative effect and guiding formulation of subsequent treatment schemes, and the application prospect is wide.

The invention discloses a self-adaptive aid decision-making method, system and device for patient radiotherapy, and a medium, and relates to the field of smart medical treatment. The method comprises the following steps: standardizing and preprocessing multi-source original data; performing automatic segmentation and change detection on tumor and normal tissues based on the processed data; delineating a tumor target region and a normal tissue in radiotherapy in a detection result; generating radiation therapy dose distribution according to the sketching result; evaluating the radiation treatment dose distribution by adopting an optimization evaluation method to generate a plurality of alternative treatment schemes; determining an optimal treatment regimen based on the plurality of alternative treatment regimens; and performing radiotherapy based on the optimal treatment scheme, monitoring anatomical changes of the patient in real time in the radiotherapy process, and dynamically adjusting the optimal treatment scheme. According to the invention, a plurality of operations of patient radiotherapy can be effectively integrated, and precision and individuation of patient radiotherapy can be realized, so that complex changes in the treatment process can be better coped with, and the overall treatment effect can be improved.

The invention discloses a tumor and target region synchronous segmentation method and system based on visual language guidance. The method comprises the following steps: constructing a multi-modal data set fusing a medical image and a clinical text; a unified encoder is adopted to extract shared visual features, a double-branch decoder is adopted to predict a tumor region (GTV) and a clinical target region (CTV) respectively, and information sharing and task differentiation modeling are achieved; introducing a medical pre-training large language model, and respectively extracting language features related to GTV and CTV; a visual language collaborative attention module is designed, dynamic fusion and alignment of visual languages are carried out, task related semantics are guided and enhanced, and redundant information is inhibited; and outputting a precise synchronous segmentation result of the GTV and the CTV after fusing the multi-modal features. Compared with an existing scheme, the problems that the boundary of a tumor target region in a medical image is fuzzy and multi-modal information is insufficient in utilization are effectively solved, the segmentation precision and robustness are remarkably improved, and reliable support is provided for clinical radiotherapy planning.

The invention discloses a real-time respiratory movement prediction and compensation method for thoracic and abdominal radiotherapy. A respiratory signal acquisition module, a respiratory movement prediction module, a body surface mark point position monitoring module, a body surface mark point displacement prediction module, a body surface mark point coordinate conversion module, a tumor target center point prediction module and a tumor target visualization module are included. The invention discloses a respiratory movement prediction system based on a causal convolutional network, and the system achieves the precise prediction of the position of a tumor target region in the future by collecting a respiratory waveform signal and a body surface mark point movement track of a patient in real time, extracting a periodic movement mode, and predicting the three-dimensional displacement of the tumor target region in 0.5-2 seconds in the future.

The invention provides a tumor target pose real-time tracking and predicting method and system, equipment and a medium. An abdominal respiration monitoring device of the system is used for detecting abdominal respiration deformation; the multi-channel array flexible acquisition sensor has deformability and is used for detecting back myoelectricity and pressure change signals; the body surface information acquisition device is used for acquiring chest and abdomen point cloud data of a human body; and the main controller is used for processing data acquired by the abdominal respiration monitoring device, the multi-channel array flexible acquisition sensor and the body surface information acquisition device to obtain a predicted position of an active tumor target region. In order to solve the problem of respiratory movement in the radiotherapy process, back pressure myoelectricity information, abdomen respiratory deformation information and binocular vision information respiratory movement evaluation are adopted, and a mapping relation from in-vitro movement to in-vivo tumor movement is constructed through in-vitro multi-modal data and 4D-CT information in combination with a big data model. And in-vivo tumor pose prediction and evaluation are realized.

The invention discloses an enzyme response type KRAS targeted protein degradation chimera as well as a preparation method and application thereof, and belongs to the technical field of tumor targeted therapy. The enzyme response type KRAS targeted protein degradation chimera disclosed by the invention is obtained by covalently linking three parts, namely a KRAS targeted protein degradation chimera, an enzyme response type amino acid sequence and a cell penetrating peptide amino acid sequence, wherein the KRAS targeted protein degradation chimera is obtained by linking a KRAS targeted peptide and a VHL E3 ligase ligand through succinic acid. The enzyme response type KRAS targeted protein degradation chimera releases the KRAS targeted protein degradation chimera under the action of ATG4 enzyme shearing, and shows a relatively strong lung cancer resisting effect in vitro and in vivo. The invention has significant advantages in the aspect of antitumor drugs, and opens up a new field for the development of targeted protein degradation chimera drugs. Enzyme response type KRAS targeted protein degradation chimera molecular structural formula as follows: # imgabs0 #

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention discloses an intelligent medical management method and system based on malignant tumor radiotherapy. The method comprises the following steps: acquiring holographic image data corresponding to clinical image data of a patient; inputting the holographic image data into a trained deep learning model to identify a malignant tumor target region and attributes thereof; calculating the dose of radioactive particles based on the malignant tumor target region and the attributes thereof; generating a 3D printing instruction according to the malignant tumor target region; obtaining dose distribution monitoring data of radioactive particles in the treatment area; analyzing the uniformity of radioactive particles according to the dose distribution monitoring data; and according to the malignant tumor target region, the attributes and the uniformity of the radioactive particles, generating a treatment scheme and performing treatment risk assessment. Effective connection of all links can be achieved, the treatment time of a patient is shortened, and the treatment effect is improved.

The invention discloses a metal polyphenol network modified drug-loaded radioactive microsphere as well as a preparation method and application thereof, radionuclides are labeled on different microspheres by a precipitation method or an adsorption method, and the metal polyphenol network is modified on the surface of the radioactive microsphere to improve the nuclide labeling stability and the synchronous drug loading capability of the radioactive microsphere. Subsequently, medicine molecules can be adsorbed to the modified radioactive microspheres to obtain the metal polyphenol network modified medicine-carrying radioactive microspheres. The metal polyphenol network modified drug-loaded radioactive microspheres prepared by the invention can solve the problems of radionuclide non-target shedding and DNA damage repair caused by nuclear drugs, avoid secondary drug administration, ensure that drugs directly and accurately reach tumor targets, and improve the drug delivery efficiency. And the selective internal irradiation therapy based on radioactive microsphere mediation is further promoted to play a more effective tumor treatment effect.

The invention belongs to the field of biomedicine, and particularly relates to polypeptide for targeted blocking of combination of TRIM25 and BRD7 protein and application of the polypeptide. According to the present invention, based on the minimum binding region PRYSPRY structural domain (439 aa-630 aa) of the TRIM25 and the BRD7 protein, the blocking peptide TB16 capable of specifically blocking the mutual binding of the TRIM25 and the BRD7 protein is screened, such that the ubiquitination degradation of the BRD7 is inhibited, and the stability of the BRD7 tumor inhibition protein is improved. The polypeptide drug TB16 can effectively inhibit breast cancer, nasopharynx cancer, ovarian cancer, lung cancer and liver cancer cell proliferation and breast cancer in-vivo tumor growth, has good anti-solid tumor activity, and is expected to become a new anti-tumor targeting drug.

The invention relates to the technical field of tumor image processing, in particular to a method for improving tumor radiotherapy target area sketching precision. The method comprises the following steps: acquiring an edge connecting line for connecting a central pixel point and different edge pixel points in a possible tumor region; according to the gray level distribution of the pixel points on each edge connecting line, the pixel gray level uniformity of each edge connecting line is obtained, and a connecting line cluster is obtained; analyzing the position distribution characteristics of edge connecting lines in different connecting line clusters and the number of the connecting line clusters, and obtaining the overall gray uniformity of each possible tumor region; obtaining the tumor credibility of each tumor possible region by combining the gray distribution of the boundary pixel points in each tumor possible region and the boundary morphological characteristics of each tumor possible region; an optimal tumor area is obtained, and a tumor target area is sketched. According to the invention, the accurate gray scale range of the tumor area is obtained, so that the target area sketching precision is improved.

The present disclosure is a polyethylene glycol modified zwitterionic fluorescent probe. The core luminescent group of the fluorescent probe of the present disclosure is a heptamethine chain which is connected by a phenoxy bridge and has a rigid ring structure in the center. The two ends of the heptamethine chain are two sulfonic indole groups, and two polyethylene glycol chains are connected with the indole groups. A tumor targeting ligand is connected with a luminescent group through one polyethylene glycol chain and one alkaline amino acid spacer. The probe of the present disclosure can be connected with polypeptides, small molecules and antibodies having a tumor targeting function, thereby achieving near-infrared fluorescence imaging for tumor targeting. The probe of the present disclosure has good druggability, and is extremely suitable for industrial production and clinical promotion.

The invention provides a bispecific antibody targeting CD3 and tumor targets and application thereof. The bispecific antibody comprises a first antigen binding region, a second antigen binding region and an Fc part, the Fc part comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein of a first molecule or a fragment thereof, the binding protein of the first molecule or the fragment thereof is connected with the N end of the scFv fragment, and the C end of the scFv fragment is connected with the N end of the first Fc peptide fragment; the second antigen binding region comprises a binding protein of a second molecule or a fragment thereof, and the binding protein of the second molecule or the fragment thereof is connected with the N end of the second Fc peptide fragment; the first molecule and the second molecule are the same, and the scFv fragment has CD3 binding activity. The bispecific antibody is weak in combination with T cells, strong in combination with tumor cells, good in safety, high in anti-cancer activity and high in clinical application and drug development value.

The invention provides a preparation method and application of a CD70 specific nano antibody molecular imaging probe. The probe comprises a tumor targeting group, radionuclide and a bifunctional chelating agent, the tumor targeting group is a CD70 specific nano antibody; the CD70 specific nano antibody is R8B4, and the amino acid sequence of the R8B4 is as shown in SEQ ID No. 1. The probe provided by the invention can realize noninvasive diagnosis of solid tumors such as renal clear cell carcinoma and malignant tumors of a blood system; reabsorption of the compound in the kidney is effectively inhibited through charge adjustment, kidney uptake is remarkably reduced, non-specific signals are reduced, the signal-to-noise ratio during targeted imaging or treatment is increased, and the imaging quality and treatment safety are improved. The probe not only has a wide application prospect in tumor diagnosis, but also provides a new technical support for targeted therapy and individualized precision medical treatment, and has important scientific research and clinical application values.

The invention discloses a 2.5 D dual-scale wavelet SAM-GAN liver tumor target region segmentation method, which comprises the following steps: establishing a segmentation model which is composed of a preprocessing module, a generation module and a discrimination module; an original image enters the preprocessing module and is subjected to neighborhood slice feature aggregation and anatomical perception to generate a 2.5 D image, the 2.5 D image is optimized and enhanced in the generation module and then input into the judgment module, and the judgment module evaluates the authenticity of the image output by the generation module and provides feedback training for the generation module. According to the method, the defects in the prior art can be overcome, the feature extraction capability on the liver tumor data set is improved, and the training stability and the model generalization capability are enhanced.

The invention belongs to the field of tumor drug research, and particularly relates to a cell vesicle co-delivery system, an anti-tumor drug and application. The cell vesicle-like co-delivery system is constructed according to the following steps: co-transfecting a recombinant expression vector of tumor targeting protein or targeting peptide and a recombinant plasmid of circRNA of effector molecules related to pyroptosis to a tool cell, and collecting to obtain the cell vesicle-like co-delivery system, a recombinant expression vector of the tumor targeting protein or the targeting peptide contains a DNA sequence for coding MCP protein, and a recombinant plasmid of circRNA of an effector molecule related to pyroptosis contains a DNA sequence for coding MS2 protein. According to the cell vesicle co-delivery system provided by the invention, tumor cell death is directly induced by delivering the cell death related effector molecule RNA through the cell vesicles, the killing efficiency is high, the side effect is relatively small, and the problems of mass production and drug loading can be solved.

The invention belongs to the technical field of biology, and particularly relates to a composition for tumor targeted therapy, hydrogel and a preparation method and application thereof. The tumor targeted therapy composition provided by the invention comprises the aging tumor cells and the celecoxib, the immune activation function of the aging tumor cells is that STCs can effectively activate the maturation of dendritic cells and the immune function of T cells and NK cells, SASP of the STCs is regulated through the celecoxib, especially generation of prostaglandin E2 is inhibited, and the tumor targeted therapy effect is improved. And the combined use further enhances the anti-tumor immune effect.

Disclosed in the present invention are an ecteinascidin compound and the use thereof. Provided in the present invention is a compound as represented by formula (I), or a pharmaceutically acceptable salt, an ester, a stereoisomer, a tautomer, a polymorph, a solvate, an isotopically labeled compound, a metabolite or a prodrug thereof. The compounds provided by the present invention have one or more effects selected from the following group: (1) having an inhibitory activity against tumor cell proliferation in vitro; (2) having a tumor inhibition effect in vivo; (3) having an in vivo tumor targeting capability; and (4) having good safety in vivo.

The invention discloses an AuAgPt ternary alloy nano-framework, a preparation method thereof and application of the AuAgPt ternary alloy nano-framework in anti-tumor preparations, and belongs to the field of biomedical nano-materials. The AuAgPt ternary alloy nano frame is a hollow octahedral nano frame formed by 12 AuAgPt ternary alloy edges, and the nano frame has plasmon photothermal conversion performance, catalase activity and peroxidase-like activity, and can be used for preparing the nano frame. The aptamer has the characteristics that the aptamer can form a covalent bond with glutathione (GSH), the aptamer with the framework surface capable of being modified and specifically bound with tumor cells is used for tumor targeted delivery and the like, the aptamer can be bound in a targeted manner and internalized into the tumor cells, and after near-infrared laser irradiation, the cell temperature can be increased to 42 DEG C, reactive oxygen species (ROS) can be generated, GSH can be consumed, and the tumor targeting effect is achieved. In addition, the content change of small molecule metabolites in cells can be driven through a low-temperature photothermal effect, the metabolic state is disturbed, the redox balance in the cells is destroyed, the tumor cells are induced to generate ferroptosis and apoptosis, and the low-temperature photothermal treatment of tumors is realized.

The present invention relates to combination therapies employing tumor targeted anti-CEA / CD3 bispecific antibodies and / or agents blocking PD-L1 / PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules that also target FAP, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

The invention discloses a tumor targeting reagent and application thereof in tumor diagnosis. The targeting reagent has strong affinity to tumors, strong specificity and no biotoxicity, is relatively stable in vivo, and can be used as a molecular probe to be applied to molecular imaging and / or treatment of various integrin alpha6 high-expression tumors; the targeting reagent provided by the invention comprises the tumor targeting peptide RWYDeA, and further comprises a radionuclide chelating agent, other connecting structures and a hydroxyl substitution structure, and the structure is beneficial to improving the tumor targeting property of the targeting reagent, prolonging the tumor binding time and achieving a better tumor diagnosis effect; the method can be used for preparing products for diagnosing / treating diseases related to high expression of integrin alpha6.

The invention discloses a multifunctional nano-enzyme as well as a preparation method and application thereof, and belongs to the technical field of nano-enzyme synthesis. Aiming at the problems that a traditional nano-enzyme is single in activity, limited in treatment effect, poor in tumor active targeting specificity and the like, the multifunctional nano-enzyme provided by the invention is simple and efficient in preparation method, and is prepared by taking N and P double-doped hollow carbon nanospheres as a carrier, loading L-arginine and glucose oxidase and taking an aptamer as a targeting molecule. The multifunctional nano-enzyme is small in particle size, high in dispersion degree and good in biological safety. The multifunctional nano-enzyme not only has the activities of peroxidase, nitric oxide synthase and glucose oxidase, but also has excellent photo-thermal conversion capacity in tumor targeted therapy. The multifunctional nano-enzyme provided by the invention has a tumor focus specific recognition capability, can be highly enriched at a tumor part, finally realizes the purpose of photothermal / catalytic treatment combined tumor treatment, and provides a new thought and platform for tumor treatment.

The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and / or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.

The invention provides a boron drug with tumor targeted release capability for boron neutron capture therapy and a preparation method thereof, relates to the technical field of tumor therapy, and provides a boron drug which can be activated through high-concentration NAD (P) H at a tumor site and can release a B-10 drug in a targeted manner for boron neutron capture therapy. A boron-10-containing compound in the boron medicine is connected with 3-aldehyde quinoline salt through a self-elimination reactive group, the 3-aldehyde quinoline salt can be specifically reduced by NAD (P) H rich in tumor cells to trigger chain reaction, and the effective boron-10 compound is released for boron neutron capture therapy. The damage to normal cells in the BNCT process can be effectively reduced by a method for targeted aggregation of the boron drug in the tumor cells. The boron drug synthesis method is simple, mild in condition and high in yield, has the advantages of stable chemical property, good light stability, small toxicity and the like, and provides a good application prospect for the field of boron neutron capture therapy.

The invention relates to an HER2 (human epidermal growth factor receptor 2) targeting antibody coupling gold (III) porphyrin medicine as well as a synthesis method and tumor treatment application thereof. The antibody coupling gold (III) porphyrin drug targeting HER2 is formed by connecting an anti-HER-2 trastuzumab and an A3B type gold (III) porphyrin complex through a linker, and the linker comprises a maleimide joint connected with an antibody and a self-elimination joint connected with the A3B type gold (III) porphyrin complex. The A3B type gold (III) porphyrin complex with anti-tumor activity is combined with trastuzumab with a specific recognition function as a carrier, the antibody is utilized to accurately strike tumor cells, a medicine is delivered to a tumor environment, the tumor targeting property of the gold (III) porphyrin complex is improved, and accurate treatment is realized. Distribution of drugs in the body can be improved, accumulation of the drugs in non-tumor sites can be reduced, the dosage of metal complexes is reduced, and toxic and side effects are reduced; the efficient delivery of gold drugs to tumor tissues can also be realized, and the cancer treatment effect is improved.

The invention discloses a chimera for targeted degradation of GPX4 based on HSP70 protein as well as a preparation method and application of the chimera, and belongs to the technical field of biological medicines. According to the invention, 12 chimeras for targeted degradation of GPX4 are prepared by using the technology. The HSP70 molecular chaperone complex mediated protein targeted degradation chimera provided by the invention can rapidly and durably induce the degradation of GPX4. Meanwhile, the chimeras have obvious anti-proliferative activity on GPX4 high-expression cell strains and high-selectivity induction of ferroptosis of cells, and have important significance on tumor targeted therapy and drug resistance overcoming.